Live Breaking News & Updates on ஆஸ்ட்ராலேஷியந் லுகேமியா
Stay updated with breaking news from ஆஸ்ட்ராலேஷியந் லுகேமியா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Final Results of Bioavailability Study of Phebra s Oral Arsenic Capsule for Acute Promyelocytic Leukaemia (APL) Confirm Bioequivalence of Oral and IV Formulations News provided by Share this article SYDNEY, May 13, 2021 /PRNewswire/ Australian pharmaceutical group Phebra ( Company ) congratulates the Australasian Leukaemia and Lymphoma Group (ALLG) on the release of their abstract EP433 at the virtual European Hematology Association (EHA) 2021 Conference. The abstract builds on the initial bioequivalence data from the first phase of the trial, published at EHA in June 2019 and reveals the final results from the ALLG APML5 bioavailability study undertaken by the ALLG at hospitals across Australia in 31 patients with previously untreated APL. ....
SYDNEY, May 14, 2021 /PRNewswire/ Australian pharmaceutical group Phebra (‘ Company‘) congratulates the Australasian Leukaemia and Lymphoma Group (ALLG) on the release of their abstract EP433 at the virtual European Hematology Association (EHA) 2021 Conference. The abstract builds on the initial bioequivalence data from the first phase of the trial, published at EHA in June 2019 and reveals the final results from the ALLG APML5 bioavailability study undertaken by the ALLG at hospitals across Australia in 31 patients with previously untreated APL. The aim of the APML5 study, was to characterise the bioavailability of Phebra’s oral arsenic trioxide (ATO) capsules and intravenous ATO in patients undergoing standard-of-care consolidation therapy by comparing the total arsenic AUC ....